Kit, system and method of treating myeloma patients

• US 8,672,869 B2
• Filed: 10/30/2007
• Issued: 03/18/2014
• Est. Priority Date: 10/30/2007
• Status: Active Grant

• Current Assignee: Bellco SRL (Medtronic Plc)
• Original Assignee: Bellco SRL (Medtronic Plc)
• Inventors: Wratten, Mary Lou, Atti, Mauro, Santoro, Antonio
• Primary Examiner(s): SU, SUSAN SHAN
• Application Number:
  US11/928,881
• Publication Number:
  US 20090112146A1
• Time in Patent Office: 2,331 Days
• Field of Search: 210/645, 604/5.04, 604/6.09
• US Class Current: 604/5.04
• CPC Class Codes: A61M 1/3472 with treatment of the filtrate
• CPC Class Codes: A61M 1/3486 Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
• CPC Class Codes: A61M 1/3679 by absorption A61M1/3675 takes precedence
• CPC Class Codes: A61M 2202/0417 Immunoglobulin
• CPC Class Codes: A61M 2202/0445 Proteins

Abstract

Circulating free lambda and kappa free light chains in blood play a role in the pathogenesis of acute renal failure due to myeloma. Coupled plasma filtration and adsorption allows separation of plasma from blood and treatment of the plasma through a cartridge containing a sorbent or resin material, such as hydrophobic divinylbenzene styrenic resins having an average bead diameter of 75 microns, an average pore diameter of 30 nm, and a surface area of 700 m2/g. Lambda and kappa free light chain concentrations progressively decrease during coupled plasma filtration and adsorption treatment resulting in significant reductions by the end of the treatment.

Claims

1. A method of treating a patient having myeloma, the method comprising the steps of:

treating the myeloma patient before development of acute renal failure in the patient by extracting and separating the patient'"'"'s plasma from the patient'"'"'s blood;

removing elevated levels of either lambda or kappa free light chains or both from the patient'"'"'s plasma by contacting the extracted and separated plasma with a hydrophobic resin, an ion exchange resin, a silica resin or a combination thereof to obtain purified plasma; and

re-infusing the purified plasma into the patient.

2. The method of claim 1, wherein the step of removing elevated levels of free light chains further comprises removing elevated levels of either lambda or kappa free light chains or both without removing more than about ten percent serum albumin.

3. The method of claim 1, wherein the step of removing elevated levels of free light chains further comprises selectively removing either lambda or kappa free light chains or both by contacting the plasma with a hydrophobic resin.

4. The method of claim 1, wherein the step of removing elevated levels of free light chains further comprises selectively removing either lambda or kappa free light chains or both by contacting the plasma with an ion exchange resin, a bonded silica resin, or a combination thereof.

5. The method of claim 1, wherein the step of removing elevated levels of free light chains further comprises selectively removing either lambda or kappa free light chains or both by contacting the plasma with a hydrophobic polystyrene resin.

6. The method of claim 1, further comprising the step of administering a drug to the patient for treating myeloma or effects thereof.

7. A method of preventing acute renal failure in a patient diagnosed with myeloma, the method comprising the step of purifying the plasma of the myeloma patient before development of acute renal failure in the patient after extracting and separating the patient'"'"'s plasma from the patient'"'"'s blood by contacting the extracted and separated plasma with a hydrophobic resin, an ion exchange resin, a silica resin, or a combination thereof to simultaneously reduce levels of either lambda or kappa free light chains or both;

and reduce the levels of inflammatory mediators or uremic toxins.

8. The method of claim 7, wherein the inflammatory mediators comprise interleukin 6 in the patient'"'"'s blood, vascular endothelial growth factor, or tumor necrosis factor or combinations thereof.

9. A method of using a hydrophobic resin, an ion exchange resin, a silica resin or a combination thereof to treat a patient having myeloma, wherein the hydrophobic resin, ion exchange resin, silica resin or combination thereof removes elevated levels of either lambda or kappa free light chains or both from plasma of the patient before development of acute renal failure in the myeloma patient by contacting the patient'"'"'s plasma with the hydrophobic resin, ion exchange resin, silica resin or combinations thereof after the patient'"'"'s plasma has been extracted and separated from the patient'"'"'s blood.

10. The method of claim 9 wherein the lambda or kappa free light chains are removed using a hydrophobic resin.

11. The method of claim 9 wherein the lambda or kappa free light chains are removed using a hydrophobic polystyrene resin.

12. The method of claim 9 wherein the hydrophobic resin, ion exchange resin, silica resin or a combination thereof removes residual lambda and kappa free light chains and smaller toxins with a molecular weight less than 20,000 Daltons.

13. The method of claim 9 wherein the hydrophobic resin, ion exchange resin, silica resin or a combination thereof removes no more than about 10 percent serum albumin.